Elan welcomes new Vice President of Manufacturing Services Operations

Philip Pratten moves from Catalent Pharma Solutions

Philip Pratten joined the EDT team as Vice President of Manufacturing Services Operations. Pratten previously worked at Catalent Pharma Solutions and has held positions with Cardinal Health, GlaxoWellcome and the Wellcome Foundation. He has almost 30 years of broad based experience in the pharma industry and graduated with a degree in biophysical science from North East London Polytechnic (now University of East London).

You may also like

Regulatory

Alkermes to initiate second Phase III study of ALKS 3831 for schizophrenia

ENLIGHTEN-2 will evaluate weight gain profile of novel, once-daily, oral investigational medicine compared with olanzapine
Regulatory

Alkermes initiates phase 1 clinical study of new CNS drug candidate

Novel, oral investigational medicine for the treatment of agitation in Alzheimer’s disease and other psychiatric indications
Regulatory

Alkermes achieves milestones for CNS medicines

Alkermes has announced new developments and milestones related to its proprietary product and late-stage pipeline portfolio of medicines for the treatment of central nervous system (CNS) diseases
Finance

Alkermes reports third quarter 2015 financial results

Commercial launch of Aristada underway following FDA Approval for the treatment of Schizophrenia on 5 October 5, 2015
Regulatory

FDA approves Aristada for treatment of schizophrenia

Alkermes drug is first long-acting atypical antipsychotic with both once-monthly and six-week dosing options
Finance

Alkermes to sell manufacturing plant at Gainesville, GA to Recro Pharma

Recro will make an initial cash payment of US$50m, followed by milestones of up to $120m
Regulatory

Alkermes receives Notices of Allowance for US patents for four CNS pipeline candidates

Represent novel therapeutic approaches with potential to address unmet needs in their respective disease areas
Subscribe now